An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

A Proof of Concept Study of the Effects of QAX576 (an Interleukin-13 Monoclonal Antibody) on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen

This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever

Inclusion Criteria:

• History of allergic rhinitis.

Exclusion Criteria:

• Respiratory disease other than mild intermittent asthma.
• Received immunotherapy in past 3 years.
• History of clinically significant drug allergy.
• History of clinical schistosomiasis or travel within 6 months prior to or following study to an area with endemic schistosomiasis.
• History of exposure to human therapeutic antibodies, immunoglobulins or other plasma products.

Other protocol-defined inclusion/exclusion criteria may apply